Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Imatinib Mesylate in Chordoma.

Trial Profile

Phase II Study of Imatinib Mesylate in Chordoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Feb 2012 Results reported in the Journal of Clinical Oncology indicate that imatinib has some antitumor activity in this orphan disease and is worthy of further investigation.
    • 02 Sep 2011 Additional location (Switzerland) identified as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Actual patient number (55) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top